FDA approves Tabrecta for metastatic NSCLC with mesenchymal-epithelial transition exon 14 skipping

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

A patient recently asked me a question I suspect many thoracic surgeons will soon be hearing.

August 07, 2026

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

The recent retraction of the LungTIME-C01 randomized trial evaluating chrono-modulated immunotherapy in non-small cell lung cancer has ignited a vigorous debate regarding the promise of cancer chronotherapy.

July 31, 2026

Vol.52 No.30

By Zachary S. Buchwald and Michael C. Lowe

Drugs & Targets

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

FDA approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Sigvotatug vedotin, an integrin beta-6 directed antibody-drug conjugate, did not show a statistically significant improvement in the primary endpoint of overall survival, compared to docetaxel, according to the results of the phase III SigVie-002 study (previously known as Be6A Lung-01).

June 26, 2026

Vol.52 No.25

Clinical Roundup

PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer

Novartis announced data from PSMAddition demonstrating improved prostate-specific antigen responses with Pluvicto (lutetium (177Lu) vipivotide tetraxetan) combined with standard-of-care in PSMA-positive metastatic hormone sensitive prostate cancer.

May 22, 2026

Vol.52 No.20

Drugs & Targets

FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC

FDA has granted Hyrnuo (sevabertinib) priority review status for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations in patients with no prior therapy.

May 22, 2026

Vol.52 No.20

FDA approves Tabrecta for metastatic NSCLC with mesenchymal-epithelial transition exon 14 skipping

YOU MAY BE INTERESTED IN

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer

FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login